SHP2在非小细胞肺癌中的表达及意义  

Expression and Its Clinical Significance of SHP2 in Non-small Cell Lung Cancer

作　　者：唐春兰[1] 周向东[1] 杨和平[1] 王清良[2] 章容[2] 

机构地区：[1]第三军医大学西南医院呼吸内科,重庆400038 [2]第三军医大学西南医院病理研究所,重庆400038

出　　处：《中国肺癌杂志》2010年第2期98-101,共4页Chinese Journal of Lung Cancer

基　　金：重庆市自然科学基金(No.CSTC-2005BB5299)资助~~

摘　　要：背景与目的以往研究表明,异常的酪氨酸磷酸化与癌的发生密切相关,本研究旨在采用组织芯片技术结合免疫组化方法来研究蛋白酪氨酸磷酸酶SHP2在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及意义。方法80例NSCLC石蜡标本制成组织芯片,采用链菌素亲生物素-过氧化物酶法(SP)进行免疫组化检测。结果SHP2在NSCLC中的表达率为70.00%(56/80),其中鳞癌为72.5%(29/40),腺癌为67.50%(27/40);有无淋巴结转移的患者SHP2的阳性表达率分别为73.61%(53/72)和37.50%(3/8)(P<0.05);SHP2的表达与患者性别、年龄、肿块大小、病理类型、分化程度、临床分期间无统计学差异(P<0.05)。结论SHP2在NSCLC中有较高的表达率,且与淋巴结转移密切相关,提示肺癌的发生、发展可能与SHP2有关,SHP2可能是肺癌新的标志物及治疗靶点。Background and objective Precious studies proven that aberrant tyrosine phosphorylation has linked with cancer.The aim of this work is to study the expression and significance of SHP2 in non-small cell lung cancer （NSCLC） through tissue microarray technique and immunohistochemical method.Methods Eighty NSCLC specimens were constructed into tissue microarray and performed using immunohistochemistry.Results The total positive rates of SHP2 were 70.7% （56/80） in NSCLC,72.5% （29/40） in squamous cell carcinoma and 75% （27/40） in adenocarcinoma,which was not significant difference in sex,age,the size of tumor,histology,clinical stages and differentiation （P0.05）,the positive rates of SHP2 were significantly higher in the cases with lymphnode metastasis than those without （P0.05）.Conclusion The expression rate of SHP2 is high and closely correlated to lymphnode metastasis in NSCLC,which implies the occurrence and development of lung cancer may be related to SHP2,and SHP2 may be a new marker and therapeutic targets for lung cancer.

关 键 词：肺肿瘤 组织芯片 免疫组化 SHP2 

分 类 号：R734.2[医药卫生—肿瘤]